UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)*

 

QUEST DIAGNOSTICS INCORPORATED

(Name of Issuer)

--------------------------------------------------------------------------------

 

Common Stock, $.01 Par Value

(Title of Class of Securities)

--------------------------------------------------------------------------------

 

74834L 10 0

(CUSIP NUMBER)

--------------------------------------------------------------------------------

Victoria A. Whyte, GlaxoSmithKline plc

980 Great West Road

Brentford, Middlesex TW8 9GS

Telephone: +44 (0)208 047 5000

(Name, address and telephone number of person authorized to receive notices and communications)

--------------------------------------------------------------------------------

 

March 19, 2009

(Date of Event That Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. /___/

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

This Amendment No. 8 amends and supplements the Statement of Schedule 13D electronically filed with the Securities and Exchange Commission (the “Commission”) on August 25, 1999 (the “Initial Statement”), and subsequent amendments filed electronically with the Commission on May 14, 2001, May 22, 2002, June 29, 2004, December 15, 2004, June 14, 2006, February 16, 2007 and September 18, 2008.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

The undersigned hereby further amends and supplements Items 2 and 5 of the Initial Statement to include the following information (capitalized terms used herein without definition shall have the meaning as set forth in the Initial Statement).

 

--------------------------------------------------------------------------------

 

 

1

 

 

 

 


CUSIP No. 74834L 10 0

 

 

1

Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

 

GlaxoSmithKline plc

98-0101920

 

--------------------------------------------------------------------------------------------------

 

2

Check the Appropriate Box if a Member of a Group

 

a / /

b / /

--------------------------------------------------------------------------------------------------

 

3

SEC USE ONLY

 

 

--------------------------------------------------------------------------------------------------

 

4

Source of Funds

 

OO

--------------------------------------------------------------------------------------------------

 

5

Check box if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e)

 

/ /

--------------------------------------------------------------------------------------------------

 

6

Citizenship or Place of Organization

 

England and Wales

--------------------------------------------------------------------------------------------------

 

Number of Shares Beneficially Owned by Each Reporting Person With:

 

 

7.

Sole Voting Power: 0

     

 

8.

Shared Voting Power: 30,755,151

     

 

9.

Sole Dispositive Power: 0

     

 

10.

Shared Dispositive Power: 30,755,151

  

--------------------------------------------------------------------------------------------------

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person

 

30,755,151

--------------------------------------------------------------------------------------------------

 

12

Check if the Aggregate Amount in Row (11) Excludes Certain Shares

 

/ /

--------------------------------------------------------------------------------------------------

 

 

2

 

 

 

 


CUSIP No. 74834L 10 0

 

13

Percent of Class Represented by Amount in Row (11)

 

16.5%

--------------------------------------------------------------------------------------------------

 

14

Type of Reporting Person

 

CO

--------------------------------------------------------------------------------------------------

 

 

 

 

 

 

 

 

 

3

 

 

 

 


CUSIP No. 74834L 10 0

 

Item 1. Security and Issuer

 

--------------------------------------------------------------------------------

 

Item 2. Identity and Background

 

(a)

 

(b)

 

(c)

Set forth in Schedule I to this Amendment (“Schedule I”) are the name, business address and present principal occupation or employment of each executive officer and director of the Company.

   

(d)

During the last five years, there have been no criminal proceedings against the Company or, to the best knowledge of the Company, any of the other persons with respect to whom information is given in response to this Item 2.

   

(e)

During the last five years, neither the Company nor, to the best knowledge of the Company, any of the other persons with respect to whom information is given in response to this Item 2 has been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws.

   

(f)

The citizenship of each executive officer and director of the Company is set forth in Schedule I.

 

--------------------------------------------------------------------------------

 

Item 3. Source and Amount of Funds or Other Consideration

 

--------------------------------------------------------------------------------

 

Item 4. Purpose of Transaction

 

--------------------------------------------------------------------------------

 

Item 5. Interest in Securities of the Issuer

 

(a)

Registered Name

No. of Shares

Percent

 

SB Holdings Capital Inc.

30,755,151

16.5 %

(b)

 

(c)               All shares of common stock of the Issuer (the “Shares”) previously registered in the name of SmithKline Beecham Corporation were transferred to SB Holdings Capital Inc. The reported Share amounts for SB Holdings Capital Inc. reflect amounts as of March 19, 2009. SB Holdings Capital Inc. effected the following transactions with respect to the Shares:

 

 

(i)

On March 17, 2009, SB Holdings Capital Inc. sold 500,000 Shares in the open market through J.P. Morgan Securities Inc. at a weighted average price of $45.4983 per Share, in the price range of $45.00 to $45.94.

 

(ii)

On March 18, 2009, SB Holdings Capital Inc. sold 500,000 Shares in the open market through J.P. Morgan Securities Inc. at a weighted average price of $45.7041 per Share, in the price range of $45.23 to $46.53.

 

 

4

 

 

 

 


CUSIP No. 74834L 10 0

 

 

(iii)

On March 19, 2009, SB Holdings Capital Inc. sold 237,500 Shares in the open market through J.P. Morgan Securities Inc. at a weighted average price of $44.3872 per Share, in the price range of $44.06 to $45.67.

 

(iv)

On March 19, 2009, SB Holdings Capital Inc. sold 4,511,657 Shares back to the Issuer at a price of $44.3296 per Share.

 

(d)

 

(e)

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

Item 7. Material to be Filed as Exhibits

 

 






 

5

 

 

 

 


CUSIP No. 74834L 10 0

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: March 20, 2009 

 

 

  GLAXOSMITHKLINE PLC

 

By:

/s/ Victoria A. Whyte

    Victoria A. Whyte
Deputy Company Secretary

 

 

SCHEDULE I

 

Name

Business Address

Principal Occupation or Employment

Citizenship

Board of Directors

 

 

 

Andrew Witty

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Chief Executive Officer

British

Julian Heslop

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Chief Financial Officer

British

Dr. Moncef Slaoui

709 Swedeland Road
King of Prussia, PA
19046

Executive Director
Chairman Research & Development

Belgian

Sir Christopher Gent

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

Dr. Stephanie Burns

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

USA

Lawrence Culp

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

USA

Sir Crispin Davis

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

 

 

 

6

 

 

 

 


CUSIP No. 74834L 10 0

 

 

Sir Deryck Maughan

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

Dr. Daniel Podolsky

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

USA

Sir Ian Prosser

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

Dr. Ronaldo Schmitz

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

Tom de Swaan

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

Dutch

Sir Robert Wilson

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

Professor Sir Roy Anderson

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Company Director

British

Corporate Executive Team

 

 

 

Andrew Witty

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Chief Executive Officer

British

Julian Heslop

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Chief Financial Officer

British

Daniel Troy

One Franklin Plaza
Philadelphia, PA 19102

Senior Vice President & General Counsel

USA

John Clarke

One Franklin Plaza
Philadelphia, PA 19102

President Consumer Healthcare

New Zealand

Marc Dunoyer

GSK Building
6-15, Sendagaya
4 chome, Shibuya-ku, Tokyo 151-8566

President
Asia Pacific / Japan

French

 

 

 

7

 

 

 

 


CUSIP No. 74834L 10 0

 

 

Abbas Hussain

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

President, Emerging Markets

British

Duncan Learmouth

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Senior Vice President,
Corporate Communications and Community Partnerships

British

William Louv

One Franklin Plaza
Philadelphia, PA 19102

Chief Information Officer

USA

Daniel J. Phelan

One Franklin Plaza
Philadelphia, PA 19102

Chief of Staff

USA

Claire Thomas

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Senior Vice President,
Human Resources

British

David Pulman

Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709

President,
Global Manufacturing & Supply

British

Dr. Moncef Slaoui

709 Swedeland Road
King of Prussia, PA
19046

Executive Director
Chairman, Research and Development

Belgian

David Redfern

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Chief Strategy Officer

British

Jean Stéphenne

Rue de l’Institut 89
B-1330 Rixensar
Belgium

President and General Manager, Biologicals

Belgian

Edward Gray

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

President,
Pharmaceuticals Europe

British

Simon Bicknell

980 Great West Road
Brentford
Middlesex, England
TW8 9GS

Senior Vice President, Company Secretary & Compliance Officer

British

Deirdre Connelly

One Franklin Plaza
Philadelphia, PA
19102

President, North America
Pharmaceuticals

USA

 

 

 

8